Antiarrhythmic and general cardiovascular activity of the N,N-dimethylquaternary ammonium derivative of bunolol.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004566:Electrodes; D005730:Ganglionic Blockers / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D002040:Levobunolol / Q000494:pharmacology* / Q000627:therapeutic use; D009638:Norepinephrine / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D007328:Insulin; D000644:Quaternary Ammonium Compounds; D010042:Ouabain; D010672:Phenytoin; D011433:Propranolol; D002040:Levobunolol; D009638:Norepinephrine